HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

2nd Edition of Cardiology World Conference

September 17-18, 2021 | Paris, France

September 17-18, 2021 | Paris, France

Mila Jakovljevic

Keynote Speaker for Cardiology Conference 2021- Mila Jakovljevic
Mila Jakovljevic
Polyclinic for Cardiovascular Diseases and Prevention,  Croatia
Title : Integrative metabolic therapeutic approach for symptomatic patients with left ventricular dilatation and reduced ejection fraction


Abstract: Introduction & Aim: Myocardial energetics has a central role in the pathophysiology of heart failure. Our hypothesis was that cardiac metabolic therapeutic approach must be integrative, improving both the substrate utilization and the complete substrate oxidation, i.e. supporting normal mechanism of energy production without increased generation of reactive oxygen species. Since the energy metabolism is closely linked to cardiac function, we assessed the effect of the integrative metabolic approach on the functional ability and quality of life in patients with heart failure and reduced ejection fraction /HFrEF/.

Methods and results: We investigated 33 patients with left ventricular dilatation /LVIDd>60 mm/ and reduced ejection fraction /EF<40%/ in 76 complementary supportive therapy /CST/ periods. Prior to each CST period,therapy was optimized /OMT/ for one month. CST consisted of a 10-day session. In addition to OMT,the patients were treated with carnitine, L-arginine, magnesium, vitamin B, coenzyme Q-10, vitamin E, vitamin C and selenium while lying for 30 minutes inside a pulsed electromagnetic field with intensity of up to 30 microteslas and inhaling negatively ionized oxygen. Before and after each CST period, patients were asked to evaluate the quality of life using the Minnesota Living with Heart Failure Questionnaire /MLHFQ/ and the visual analogue scale /VAS/, EF, LVIDd and NYHA classes were determined. Statistical analysis was based on the t-test, Spearman's rank correlation coefficient and Wilcoxon's signed-ranks test. The longest observation period was 122 months.

After administering the metabolic supportive therapy, a statistically significant improvement /p<0,05/ was noticed in particular items of the MLHFQ, in emotional and physical dimensions. The values of VAS and EF increased whereas the values of NYHA and LVIDd decreased significantly /p<0,001/.

Conclusion: Integrative metabolic therapeutic approach significantly improved the functional capacity and quality of life in patients with HFrEF.




Mila Jakovljevi? completed her specialisation in internal medicine at the Department for Heart and Blood Vessel Diseases, Zagreb University Hospital Centre. She subsequently completed a programme in cardiology and clinical pharmacology and gained a doctorate degree in medical sciences at the University of Zagreb covering topics from the field of cardiology. Now she is the director of Saint Nicholas Polyclinic for Cardiovascular Diseases and Prevention, Croatia